22 completed, 4 unknown, 1 active not recruiting, 1 withdrawn. 28 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 28 | Completed 22, Unknown 4, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 6 | Unknown 3, Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow Candidiasis: new trials by email Literature Review of Candidiasis trials Research Report on Candidiasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CelAgace™ OraRinse Solution for Treatment of Candidiasis silver citrate complex and acemannan - Candidiasis, Oral | Phase 1 / Phase 2 | Unknown | CelaCare Technologies, Inc. | 15 | 2024-09-01 | 2024-02-09 |
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| Safety and Tolerability Studies of CanProFem-AK, Vaginal Suppositories in Healthy Volunteers CanProFem-AK - Candidosis Vaginal | Phase 1 | Completed | Industrial Microbiology LLP | 20 | 2024-06-01 | 2024-08-02 |
| Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis Nitric Oxide - Candidiasis, Oral | Phase 1 | Completed | Sanotize Research and Development corp. | 6 | 2024-01-20 | 2024-07-10 |
| Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study Vaccine - Recurrent Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Active not recruiting | LimmaTech Biologics AG | 251 | 2023-12-06 | 2026-03-04 |
| Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp Ibrexafungerp - Vulvovaginal Candidiasis, Candida Infection | Phase 1 | Completed | Scynexis, Inc. | 5 | 2023-07-12 | 2025-08-08 |
| The Anti-fungal Effect of Miconazol Versus Miconazol-Loaded Chitosan Nanoparticles Chitosan - Oral Thrush | Phase 1 | Completed | Yasmine gamil | 80 | 2023-01-10 | 2023-10-10 |
| Patients With Vulvovaginal Candidiasis EPP-AF Gel 1%, EPP-AF Gel 2%, Clotrimazole - Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | University of Sao Paulo | 90 | 2018-01-30 | 2018-10-19 |
| Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers Vorico Injection 200mg(Voriconazole), Vfend®(Voriconazole) IV 200mg - Aspergillus Infections, Candida Infections | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 24 | 2015-09-01 | 2020-03-18 |
| Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Lcr Regenerans® vaginal capsules, Lcr Regenerans® vaginal tablet - Candidiasis, Vulvovaginal | Phase 1 | Completed | Biose | 34 | 2015-07-01 | 2018-02-05 |
| A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers Lozanoc 50mg, Sporanox 100mg - Superficial Mycoses, Dermatomycoses | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 24 | 2015-07-01 | 2016-03-04 |
| Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida Medium-Chain Triglyceride (MCT) Oil - Candida Infection, Premature Infant | Phase 1 | Completed | Joseph Bliss | 12 | 2014-06-05 | 2022-06-14 |
| Rituximab for Anti-cytokine Autoantibody-Associated Diseases Rituximab - Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 7 | 2014-04-29 | 2026-10-26 |
| Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis NDV-3A, NDV-3, Placebo - Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Completed | NovaDigm Therapeutics, Inc. | 188 | 2013-07-01 | 2018-07-18 |
| Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463 TOL-463 Vaginal ovule, TOL-463 Vaginal gel - Vaginal Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 26 | 2013-04-01 | 2014-05-16 |
| Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation Micafungin - Invasive Candidiasis | Phase 1 | Completed | Kevin Watt | 18 | 2013-01-01 | 2019-11-05 |
| The Effect of Palatal Brushing on Denture Stomatitis Palatal brushing - Denture Stomatitis | Phase 1 | Completed | Université de Montréal | 48 | 2012-07-01 | 2014-01-22 |
| Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, Placebo with alum IM - Staphylococcal Infections, Yeast Infections | Phase 1 | Completed | NovaDigm Therapeutics, Inc. | 164 | 2011-09-01 | 2020-03-04 |
| Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida NDV-3 investigational vaccine - Staphylococcal Infections, Candidiasis | Phase 1 | Completed | NovaDigm Therapeutics, Inc. | 40 | 2011-01-01 | 2012-05-22 |
| Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection PEV7C1, PEV7C9, PEV7B2 - Recurrent Vulvovaginal Candidiasis | Phase 1 | Completed | Pevion Biotech Ltd | 48 | 2010-03-01 | 2012-12-24 |
Showing 20 of 28. Sign in to see all of them.
Candidiasis, Vulvovaginal (10) · Candidiasis, Oral (5) · Mycoses (5) · Candidemia (4) · Torulopsis (4) · Aspergillosis (3) · Candidiasis, Invasive (3) · Fungemia (3) · Staphylococcal Infections (2) · Vaginitis (2) · Vaginosis, Bacterial (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1) · Candidiasis, Chronic Mucocutaneous (1)
Bacterial Infections and Mycoses (28) · Infections (28) · Mycoses (23) · Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (11) · Genital Diseases (11) · Female Urogenital Diseases (10) · Genital Diseases, Female (10) · Vaginal Diseases (10) · Vulvar Diseases (10) · Vulvitis (10) · Vulvovaginitis (10) · Vaginitis (8) · Invasive Fungal Infections (7)
Micafungin (4) · Fluconazole (2) · Voriconazole (2) · Biological Products (1) · Chitosan (1) · Clotrimazole (1) · Itraconazole (1) · Methadone (1) · Nitric Oxide (1) · Oils (1) · Probiotics (1) · Rituximab (1) · Vaccines (1) · acemannan (1) · ibrexafungerp (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · NovaDigm Therapeutics, Inc. (3) · Astellas Pharma Inc (2) · National Cancer Institute (NCI) (2) · AM-Pharma (1) · Biose (1) · Boryung Pharmaceutical Co., Ltd (1) · CelaCare Technologies, Inc. (1) · Chong Kun Dang Pharmaceutical (1) · Daniel Benjamin (1) · Faith Mediplex (1) · Industrial Microbiology LLP (1) · Joseph Bliss (1) · Kevin Watt (1) · LimmaTech Biologics AG (1)
United States (15) · Brazil (2) · Canada (2) · South Korea (2) · Belgium (1) · Egypt (1) · France (1) · Kazakhstan (1) · Netherlands (1) · Nigeria (1) · Poland (1) · South Africa (1) · Switzerland (1)
Christa S Zerbe, M.D. (1) · Cobb M (1) · Daniel Benjamin, MD (1) · Elham Emami, DDS, PhD (1) · Giuseppe Pantaleo, Prof (1) · Jacqueline M. Plemons, DDS, MS (1) · Joel Epstein (1) · John P. Hennessey, Jr., Ph.D. (1) · Joseph M Bliss, MD, PhD (1) · Keith Moore, PHARMMD (1) · Kevin Watt, MD (1)
PMID 29596218, PMID 29697768, PMID 32468741, PMID 38321454
2014 (1), 2023 (1)